Sorrento Therapeutics Inc. (Nasdaq: SRNE), a maker of cancer and pain medications, has launched a new subsidiary called Ark Animal Therapeutics.
Sorrento Therapeutics’ subsidiary Ark is developing a pain medicine called resiniferatoxin, or RTX, which has shown efficacy in dogs with advanced bone cancer, the company said. It plans a filing for a Minor Use/Minor Species designation with the Food and Drug Administration later this year, and explore RTX’s use in cats and horses.
The company is also developing vaccines against recurring staph infections. Its main efforts are focused, however, on developing Cynviloq, a cancer medication that’s in late-stage human trials.